Document is current
Any future updates will be listed below
-
Authors
Schmidt, Henri
Zhang, Minsi
Chakarov, Dimitar
Bansal, Vineet
Mourelatos, Haralambos
Sánchez-Rivera, Francisco J.
Lowe, Scott W.
Ventura, Andrea
Leslie, Christina S.
Pritykin, Yuri
-
Funding
Funding for this research was provided by:
MSKCC TROT program (5T32CA160001)
GMTEC Postdoctoral Researcher Innovation Grant
HHMI Hanna Gray Fellowship
National Institutes of Health (P01 CA129243, U01 HG009395, U01 HG009395, DP2 AI171161)
Geoffrey Beene Cancer Foundation
MSK Functional Genomics Initiative
Agilent Technologies Thought Leader Award
Howard Hughes Medical Institute
National Science Foundation (CAREER 2238831)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 28 January 2025
First Online: 26 February 2025
Declarations
:
: All studies and procedures were approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee.
: Not applicable.
: S.W.L. is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus Inc. and PMV Pharmaceuticals. S.W.L. acknowledges receiving funding and research support from Agilent Technologies for the purposes of massively parallel oligo synthesis. No other authors have any competing interests.
